Navigation Links
Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

f GVAX immunotherapy for pancreatic cancer was conducted by the Johns Hopkins Sidney Kimmel Cancer Center in 14 patients who also received the immunotherapy following surgical resection of their tumor and standard adjuvant radiation and chemotherapy. As first reported in the Journal of Clinical Oncology in January 2001, three of eight patients who received the therapeutic dose levels of the immunotherapy had prolonged disease-free survival for a period of at least eight years. This outcome is considered particularly significant since all three long-term survivors were judged to be at high risk for recurrent cancer due to microscopic evidence of residual pancreatic tumor following surgery and two patients had metastatic tumor in regional lymph nodes. In addition, the three patients with prolonged disease-free survival -- but not the five who progressed and died -- showed evidence of treatment-associated antitumor immunity, including induction of T cell responses to the candidate tumor-associated antigen, mesothelin.

Pancreatic cancer is the fourth leading cause of cancer death in the United States. According to the American Cancer Society, approximately 37,170 Americans will be diagnosed with pancreatic cancer in 2007, and 33,370 are expected to die from the disease in 2007. Because symptoms are non-specific, cancer of the pancreas is rarely diagnosed at an early stage leaving surgical removal of the tumor as a treatment option for only approximately 20 to 30 percent of pancreatic cancer patients. The median survival of patients with operable cancer of the pancreas with currently available therapies is approximately 17 to 22 months.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunot
'"/>




Page: 1 2 3 4

Related medicine news :

1. Russia Reports First SARS Case
2. Uganda Reports Failure To Contain Sleeping Sickness
3. Reports of Hantavirus infection in India raise concerns
4. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
5. China Reports Yet Another Bird Flu Case
6. Cyprus Reports H5N1 Strain In Birds
7. Reports Of New Bird Flu Outbreak In China Raise Concerns
8. Reports Of Denmark’s First Case Of Human Bird Flu Fals
9. Bird Flu Spreads To Sudan & China Reports Of Another Case
10. French Face Transplant Patient Reports Feeling of Sensation in New Face
11. Budhia Is Fine, Government-constituted Medical Board Reports False
Post Your Comments:
(Date:7/29/2015)... ... 29, 2015 , ... It is unique for a health center to dedicate ... care. One that is very hands on and resident oriented, and one to which ... bringing great passion and energy, as well as a strong commitment to helping seniors ...
(Date:7/29/2015)... Wis. (PRWEB) , ... July 29, 2015 , ... ... its first two patients in a Clinical Performance Study for the Invisiport at ... 4.4 and 6 French catheter options, offers a less invasive, patient-friendly alternative to ...
(Date:7/29/2015)... ... July 29, 2015 , ... TransFlip is an all new dynamic transition pack ... for FCPX, these transitions are easy to apply and modify for any skill-level user. ... over 60 preset styles, kinetic flipping panel animations are just a few clicks away. ...
(Date:7/29/2015)... ... 29, 2015 , ... Zofran lawsuits around the nation are ... (JPML), according to court documents.* Attorneys handling Zofran lawsuits provide timely ... Lawsuit Center. , GlaxoSmithKline, the global pharmaceutical conglomerate and defendant in national Zofran ...
(Date:7/29/2015)... ... July 29, 2015 , ... The New Foundation ... which will by the end will cost the 501(c) organization nearly $1 million, will ... anti-ligature requirements. , “We took it down to the studs,” said Geraldine Leary, ...
Breaking Medicine News(10 mins):Health News:New Medical Director Readies To Take Reins at Monarch Landing 2Health News:New Medical Director Readies To Take Reins at Monarch Landing 3Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 2Health News:The New Foundation AZ Renovates Residential Dorms for Youth in Crisis 3
... American Healthcare,Corporation (Nasdaq: UAHC ), which owns ... care organization in,Tennessee, today announced financial results for ... Revenues increased five percent to $6.5 million for ... with revenues of $6.2 million for,the first quarter ...
... HILL, N.C., Nov. 4 As biopharmaceutical,companies ... development,opportunities, fixed-dose combination (FDC) products have become ... an effort to better,understand the development strategies ... study was conducted by Best Practices, LLC, ...
... program, HOUSTON, Nov. 4 Carriage Services, Inc.,(NYSE: CSV ) today announced results for the third quarter ... were as follows:, Third Quarter Selected Financial Results (amounts in millions, except per share amounts), ... Q3 ... ...
... brains mature earlier, study says , , TUESDAY, Nov. 4 (HealthDay ... have better control of their movements than boys with the ... published in the Nov. 4 issue of Neurology , ... children without the disorder did twice as well as boys ...
... produces noticeable results, study says , , TUESDAY, Nov. 4 ... or prescription painkillers are less likely to continue using ... combination of detoxification medications, rather than short-term drug therapy, ... have been shown to be effective in treating opioid ...
... decades, study shows , , TUESDAY, Nov. 4 (HealthDay News) -- ... improved significantly over the past three decades, but the first ... study shows. , The study looked at the experiences of ... heart attacks between 1979 and 2005. , "There were two ...
Cached Medicine News:Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 2Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 3Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 4Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 5Health News:United American Healthcare Corporation Announces Fiscal 2009 First Quarter Results 6Health News:New Study Provides Benchmarks for Fixed-Dose Combination (FDC) Drug Development 2Health News:Carriage Services Announces Third Quarter 2008 Results 2Health News:Carriage Services Announces Third Quarter 2008 Results 3Health News:Carriage Services Announces Third Quarter 2008 Results 4Health News:Carriage Services Announces Third Quarter 2008 Results 5Health News:Carriage Services Announces Third Quarter 2008 Results 6Health News:Carriage Services Announces Third Quarter 2008 Results 7Health News:Carriage Services Announces Third Quarter 2008 Results 8Health News:Carriage Services Announces Third Quarter 2008 Results 9Health News:Carriage Services Announces Third Quarter 2008 Results 10Health News:Carriage Services Announces Third Quarter 2008 Results 11Health News:Carriage Services Announces Third Quarter 2008 Results 12Health News:Extended Therapy Helps Drug-Addicted Teens 2Health News:Extended Therapy Helps Drug-Addicted Teens 3Health News:Sudden Death Risk Highest 30 Days After Heart Attack 2
(Date:7/29/2015)... 29, 2015 Touro College has announced that it ... for one of five media marijuana licenses to be issued ... of Health (DOH).  If CanniCare is selected, ... "Our college is supportive of medicinal development ... the Touro College System. "There is still a great deal ...
(Date:7/29/2015)... and PITTSBURGH , July 29, ... announced that it received regulatory clearance from the European ... its proposed acquisition of Perrigo Company plc (NYSE: ... Robert J. Coury commented, "Today marks yet ... acquisition of Perrigo and serves as further affirmation of ...
(Date:7/29/2015)... July 29, 2015 Legal-Bay LLC, The Lawsuit Settlement ... Goodwin in the Southern District of West ... trial that was initially set to start in November. The ... but new plaintiffs were added and now it involves 39 ... 7 th , according to an article in Reuters. The ...
Breaking Medicine Technology:Touro College Announces Support for CanniCare's Medical Cannabis License Application 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 2Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 3Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 4Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 5Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 6Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 7Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 8Mylan Announces Receipt of Unconditional Clearance from European Commission on Acquisition of Perrigo 9Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Pushes Back Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
Single side double clamp knife holder for the Vibratome 8000...
... The Starter Package is a solid ... The package includes the Vibratome Plus, ... v-block adapter, specimen mounts w/1/2" head, ... ease in all of your sectioning ...
... Package is the ultimate solution ... includes the Vibratome 3000 Deluxe ... package accessory kit, additional mounting ... 1/2" head, rotating stage, and ...
... is the best way to ... package includes the Vibratome 1500, ... blocks, v-block adapter, specimen mounts ... blade for the ultimate in ...
Medicine Products: